October 9, 2025 — Leads & Copy — Lifespan Vision Ventures is celebrating its portfolio company, Algen Biotechnologies, following the announcement of its research collaboration with AstraZeneca. The partnership aims to advance AI-powered drug discovery in immunology by combining Algen’s functional genomics and machine learning platform with AstraZeneca’s expertise. Together, they will identify and validate therapeutic targets for immune-mediated and inflammatory diseases, accelerating the development of next-generation medicines.
Harry Robb, Principal at Lifespan Vision Ventures, expressed his excitement about Algen Biotechnologies’ achievement, highlighting the strength of Algen’s technology and its potential to transform drug discovery.
Lifespan Vision Ventures supports Algen Biotechnologies in its mission to advance therapies that improve patient outcomes in age-related diseases and extend healthspan.
Algen Biotechnologies, headquartered in San Francisco, CA, is a precision therapeutics company focused on redefining drug discovery through CRISPR gene modulation and artificial intelligence. Founded by Chun-Hao Huang and Christine Du, Algen utilizes its proprietary platform, AlgenBrain™, to identify novel therapeutic targets.
Contact: info@lifespanvision.com
Source: Lifespan Vision Ventures
